Humans have been ingesting lactic acid bacteria for thousands of years. The fact that select strains can survive passage through the gastrointestinal (GI) tract, along with recent advances in high-throughput genome engineering, makes many strains suitable as mother-ships to transport and deliver molecules in the GI tract.
We have engineered L. reuteri to release recombinant proteins in situ. One of our approaches is to eliminate the need to use the bacterial secretion machinery but, instead, rely on bacteriophage-mediated lysis to release therapeutic proteins. The efficacy of our therapeutic delivery system is tested in various animal models of disease with collaborators both on- and off-campus.
VPL on Twitter!
Finally, we took the plunge! The van Pijkeren laboratory is on Twitter. We hope to connect with many colleagues in the field, share interesting articles and tweets, and -of course- share our latest news and …May 25, 2017
VPL in the news
The Van Pijkeren Laboratory is featured in several news articles that were recently published. MIT Technology Review published the article Edible CRISPR could replace antibiotics. Around the same time, the article Antibiotic alternatives, delivered by friendly microbes appeared …April 21, 2017
An exciting year!
Looking back at 2016, it has been an exciting year, no doubt! For starters, we had our website launched to showcase our work! We are very proud of the final product, and we will continue …December 29, 2016
Welcome to our new website
We’re very excited to have a new website! Check it out to meet the members of the van Pijkeren Laboratory, and to learn more about our research. We hope to keep you up to …September 13, 2016